BIONTECH
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
BIONTECH
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
Mainz, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.biontech.de
Total Employee:
1001+
Status:
Active
Contact:
+49 6131 90-840
Total Funding:
1.74 B USD
Technology used in webpage:
SPF Domain Not Resolving Mobile Non Scaleable Content Amazon Organization Schema IPv6 ReCAPTCHA JsDelivr Cloudflare JS US Privacy User Signal Mechanism
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Advisors List
Board_member
Current Employees Featured
Ugur Sahin Co-Founder and CEO @ BioNTech
Co-Founder and CEO
Christoph Huber Cofounder & deputy chair supervisory board @ BioNTech
Cofounder & deputy chair supervisory board
2008-01-01
Christoph Kröner Director DNA Process Development & Cap Technology @ BioNTech
Director DNA Process Development & Cap Technology
Jesse Dong Vice President, Peptide Chemistry @ BioNTech
Vice President, Peptide Chemistry
2020-05-01
Andreas Kuhn Senior Vice President RNA Biochemistry & Manufacturing @ BioNTech
Senior Vice President RNA Biochemistry & Manufacturing
2019-01-01
Michael Boehler Vice President Global Commercial and General Manager @ BioNTech
Vice President Global Commercial and General Manager
2020-08-01
Arvind m. Hundal Ph.d. SVP Business Development @ BioNTech
SVP Business Development
2019-05-01
Marc Wolfgang VP Technical Operations @ BioNTech
VP Technical Operations
2020-05-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-09 | PhagoMed | PhagoMed acquired by BioNTech | N/A |
| 2021-07-19 | Kite - TCR therapy | Kite - TCR therapy acquired by BioNTech | N/A |
| 2020-01-16 | Neon Therapeutics | Neon Therapeutics acquired by BioNTech | 67 M USD |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - BioNTech
Temasek Holdings
Temasek Holdings investment in Post-IPO Equity - BioNTech
European Investment Bank
European Investment Bank investment in Post-IPO Debt - BioNTech
European Investment Bank
European Investment Bank investment in Post-IPO Debt - BioNTech
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Venture Round - BioNTech
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - BioNTech
Platinum Asset Management
Platinum Asset Management investment in Series B - BioNTech
MiraeAsset Financial Group
MiraeAsset Financial Group investment in Series B - BioNTech
Jebsen Capital
Jebsen Capital investment in Series B - BioNTech
Invus
Invus investment in Series B - BioNTech
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-02 | MediGene | BioNTech investment in Post-IPO Equity - MediGene | 26 M EUR |
| 2022-01-25 | InstaDeep | BioNTech investment in Series B - InstaDeep | 100 M USD |
Official Site Inspections
http://www.biontech.de Semrush global rank: 291.45 K Semrush visits lastest month: 228.31 K
- Host name: a23-39-174-167.deploy.static.akamaitechnologies.com
- IP address: 23.39.174.167
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "BioNTech"
From Discovery to Delivery – Meet our Senior Team - BioNTech
Prior to joining BioNTech, she built and led a global shared services organization at Merck KGaA that provides global end-to-end finance, human resources, and procurement services. Lynn …See details»
Management Report on the Group and the Company for the 2020 …
BioNTech - Wikipedia
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich …See details»
BioNTech Org Chart + Executive Team - The Official Board
The organizational chart of BioNTech displays its 41 main executives including Ugur Sahin, Jens Holstein and Sierk Poetting. Toggle navigation The Official Board. Search. Search. ...See details»
Overview - BioNTech
We at BioNTech believe that adhering to the highest Corporate Governance standards positively impacts our performance and we put great importance on building trust with investors, the …See details»
BioNTech - The Org
BioNTech was founded in 2008 on the understanding that every cancer patient’s treatment should be individualized. Their vision is to provide patient-specific immunotherapies worldwide. …See details»
BioNTech
BioNTech SE An der Goldgrube 12 55131 Mainz, Deutschland. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: service@biontech.de. Unternehmen Über uns Forschung & Innovation Unsere Pipeline Produktion Karriere COVID-19 Quick …See details»
BNTX Combined Management Report 2022 - BioNTech
BioNTech SE is the parent company of the BioNTech Group and is responsible for the management and development of the Group. BioNTech SE has its registered office in Mainz, …See details»
BioNTech - Crunchbase Company Profile & Funding
BioNTech reported promising mid-stage data for its bispecific antibody PD-L1xVEGF, showing encouraging survival data as a first-line treatment for aggressive lung cancer. BioNTech's bispecific antibody BNT327 showed an …See details»
All BioNTech locations at a glance
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: service@biontech.de. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom …See details»
BioNTech SE - Devex
BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and th ... Type of organization. Service Providers . 1 office. 2008. https://biontech.de/ Similar ...See details»
BioNTech SE Company Profile - Overview - GlobalData
BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. The company's primary activities involve harnessing the immune …See details»
Corporate Governance - BioNTech
BioNTech SE. An der Goldgrube 12. 55131 Mainz, Germany. T: +49 6131 9084-0 F: +49 6131 9084-2121 service@biontech.de. CompanySee details»
BioNTech to Present Clinical and Preclinical Data Across
3 days ago Investors@biontech.de----1 BNT327, formerly also known as PM8002, was initially jointly developed by BioNTech and Biotheus Inc (“Biotheus”). Since February 2025, Biotheus …See details»
BioNTech: A company with social responsibility
BioNTech was again awarded "Prime" status by the internationally recognized rating agency ISS ESG in 2024, placing it in the top 10% of all companies rated in the Pharmaceuticals and …See details»
BioNTech Clinical Trials | Advancing Health Through Innovation
Welcome to BioNTech clinical trials. At BioNTech, we are committed to improving the health of people worldwide by developing novel medicines to address cancer, infectious diseases and …See details»
Welcome to our investor page | BioNTech
Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other …See details»
BioNTech | Our mission: basic research in mRNA technology and …
BioNTech’s portfolio contains more than 25 product candidates in clinical trials. In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline …See details»
Fake news sobre vacinas: entenda os perigos da desinformação
Feb 19, 2025 Nenhuma agência reguladora ou instituição de pesquisa reconhece essa suposta condição. Trata-se de uma narrativa infundada para desestimular a vacinação. O impacto da …See details»
BioNTech to Report First Quarter 2025 Financial Results and …
5 days ago MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter …See details»